




Results from Phase 2 Study of NTLA-2002 for Hereditary Angioedema

October 24, 2024



SHANNA
Living with hereditary
angioedema type 1

Intellia Therapeutics' Legal Disclaimer

This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements about Intellia’s beliefs and expectations regarding: the safety, efficacy and advancement of our clinical program for NTLA-2002 for the treatment of hereditary angioedema (“HAE”) pursuant to our clinical trial applications (“CTA”) and investigational new drug (“IND”) submissions, including the potential of NTLA-2002 to be a functional cure for people with HAE and the potential of NTLA-2002 to eliminate attacks after a single dose; the expected timing of regulatory filings and the initiation and completion of clinical trials, including the planned BLA submission for NTLA-2002 in 2026; and its expectations for commercial uptake, including for NTLA-2002 access conditions to be similar to other branded prophylactic HAE drugs.

Any forward-looking statements in this presentation are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to protect and maintain our intellectual property position; risks related to valid third party intellectual property; risks related to our relationship with third parties, including our licensors and licensees; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including our planned BLA submission for NTLA-2002; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete our Phase 3 study for NTLA-2002; risks related to the development and/or commercialization of any of Intellia’s product candidates, including that they may not be successfully developed and commercialized; and risks related to the results of preclinical or clinical studies, including that they may not be positive or predictive of future results. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this presentation is as of the date on its cover page, and Intellia undertakes no duty to update this information unless required by law.

Agenda

Welcome



Introduction

Dr. John Leonard *Chief Executive Officer, Intellia Therapeutics*



Review of NTLA-2002 Phase 2 Data

Dr. Danny Cohn *Internist, Department of Vascular Medicine, Amsterdam University Medical Center*



NTLA-2002 Clinical Development Update

Dr. David Lebwohl *Chief Medical Officer, Intellia Therapeutics*



Q&A

Dr. Paula Busse *Professor of Medicine – Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai*



Dr. Jim Butler *General Manager of NTLA-2002 Program, Intellia Therapeutics*

Agenda

Welcome



Introduction

Dr. John Leonard *Chief Executive Officer, Intellia Therapeutics*



Review of NTLA-2002 Phase 2 Data

Dr. Danny Cohn *Internist, Department of Vascular Medicine, Amsterdam University Medical Center*



NTLA-2002 Clinical Development Update

Dr. David Lebwohl *Chief Medical Officer, Intellia Therapeutics*



Q&A

Dr. Paula Busse *Professor of Medicine – Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai*



Dr. Jim Butler *General Manager of NTLA-2002 Program, Intellia Therapeutics*



—
SHANNA
Living with
hereditary
angioedema

NTLA-2002 Has the Potential to Transform the Hereditary Angioedema Treatment Paradigm

Goal with NTLA-2002 = **Functional Cure**



One-time treatment
of NTLA-2002

Freedom from attacks



Freedom from chronic
prophylaxis treatment

Key Learnings from the NTLA-2002 Phase 2 Study

- ✓ Deep reductions in hereditary angioedema (HAE) attacks at both dose levels tested
- ✓ Safety profile continued to be highly encouraging
- ✓ Single 50 mg dose led to majority of patients (8/11) achieving complete elimination of attacks
- ✓ 50 mg dose led to greater kallikrein and attack rate reduction vs. 25 mg dose

50 mg dose selected for Phase 3 study

Agenda

Welcome



Introduction

Dr. John Leonard *Chief Executive Officer, Intellia Therapeutics*



Review of NTLA-2002 Phase 2 Data

Dr. Danny Cohn *Internist, Department of Vascular Medicine, Amsterdam University Medical Center*



NTLA-2002 Clinical Development Update

Dr. David Lebwohl *Chief Medical Officer, Intellia Therapeutics*



Q&A

Dr. Paula Busse *Professor of Medicine – Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai*



Dr. Jim Butler *General Manager of NTLA-2002 Program, Intellia Therapeutics*

Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema

Danny M. Cohn,^{1*} Padmalal Gurugama,² Markus Magerl,^{3,4} Constance H. Katelaris,⁵ Adele Golden,⁶ Mrinal Y. Shah,⁶ David Maag,⁶ Hilary J. Longhurst⁷

¹Amsterdam University Medical Center, Amsterdam, the Netherlands; ²Cambridge University Hospitals, NHS Foundation Trust, Cambridge, UK; ³Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ⁴Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; ⁵Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia; ⁶Intellia Therapeutics, Cambridge, Massachusetts; ⁷Auckland City Hospital and University of Auckland, Auckland, New Zealand

*Presenting author

To be presented at the American College of Allergy, Asthma & Immunology (ACAAI)
2024 Annual Scientific Meeting | October 24-28, 2024, Boston, Massachusetts

Disclosures

- Dr. Cohn has acted as a consultant or speaker for or participated in research with Astria, BioCryst, CSL Behring, Intellia Therapeutics, Ionis Pharmaceuticals, KalVista, Pharming, Pharvaris, and Takeda

NTLA-2002 Phase 1/2 Trial Design

International, multicenter study to assess safety, tolerability, PK, PD and effect of NTLA-2002 on attacks in adults with Type I or Type II HAE



Intervention:

Single dose administered via an intravenous (IV) infusion

PHASE 1 Open-Label, Single-Ascending Dose

75 mg (n=3)

50 mg (n=4)

25 mg (n=3)

PHASE 2 Expansion study to confirm recommended dose

Randomized
2:2:1

50 mg (n=11)

25 mg (n=10)

Placebo arm (n=6)

PHASE 2 ENDPOINTS

PRIMARY ENDPOINT

- Number of angioedema attacks per month during primary observation period (weeks 1-16)
 - Primary analysis occurred when the 25th patient reached week 16

KEY SECONDARY ENDPOINTS

- Safety
- Number of angioedema attacks per month (weeks 5-16)
- Change from baseline in total plasma kallikrein level

Clinical Development Supporting Phase 3 Study Initiation



Trial Dynamics

<ul style="list-style-type: none"> • N = 10 patients • Open-label study, no placebo-control • No washout of chronic prophylaxis therapy • 16-week primary observation period <i>Median of 20 months of follow-up previously presented</i> 	<ul style="list-style-type: none"> • N = 27 patients • Double-blind study, randomized, placebo-control • Required washout of chronic prophylaxis therapy • 16-week primary observation period <i>Median of 8 months of follow-up</i>
---	--

Attack Rate Calculation

<ul style="list-style-type: none"> • Change in attack rate relative to patient’s baseline 	<ul style="list-style-type: none"> • Difference in attack rate relative to placebo
--	--

GOAL

<ul style="list-style-type: none"> • Evaluate safety, dose range and initial efficacy 	<ul style="list-style-type: none"> • Evaluate efficacy and safety findings in a larger number of patients to support Phase 3 dose selection
---	---

Patient Demographics and Characteristics

Characteristic		NTLA-2002 25 mg (n=10)	NTLA-2002 50 mg (n=11)	Placebo (n=6)
Median age (range), years		48.5 (34-62)	44.0 (18-61)	47.0 (31-76)
Sex, n (%)	Male	7 (70.0)	5 (45.5)	2 (33.3)
Median weight (range), kg		89 (58-133)	78 (56-107)	79 (50-92)
HAE type, n (%)	HAE-C1INH-Type1	8 (80.0)	10 (90.9)	5 (83.3)
	HAE-C1INH-Type2	2 (20.0)	1 (9.1)	1 (16.7)
Prior use of long-term prophylaxis, n (%)		6 (60.0)	6 (54.5)	5 (83.3)
Long-term prophylaxis prior to study entry, n (%)	Lanadelumab	2 (20.0)	2 (18.2)	1 (16.7)
	Attenuated androgens	2 (20.0)	1 (9.1)	2 (33.3)
	Berotrastat	1 (10.0)	2 (18.2)	1 (16.7)
	C1INH	1 (10.0)	0	1 (16.7)
	Tranexamic acid	0	1 (9.1)	0
Median no. of angioedema attacks during the historical attack period (range) ^a		6.5 (3-24)	4.0 (3-11)	5.5 (3-9)
Typical attack severity, n (%)	Mild	1 (10.0)	0	1 (16.7)
	Moderate	6 (60.0)	9 (81.8)	4 (66.7)
	Severe	3 (30.0)	2 (18.2)	1 (16.7)
Mean baseline monthly attack rate, n		3.6	3.6	3.7

^aThe historical attack period is defined as the 90 days before the screening period, which coincided with washout of any long-term prophylaxis by a patient prior to study entry. C1INH, C1 inhibitor; HAE, hereditary angioedema.


NTLA-2002 Continues to Be Well Tolerated Across All Dose Levels

TEAEs in ≥2 Patients After NTLA-2002 Administration (pooled), n (%)	NTLA-2002 25 mg (n=10)	NTLA-2002 50 mg (n=11)	Placebo (n=6)
Any TEAE	10 (100)	11 (100)	6 (100)
Headache	4 (40)	4 (36)	1 (17)
Fatigue	3 (30)	3 (27)	2 (33)
Nasopharyngitis	3 (30)	3 (27)	2 (33)
Back pain	3 (30)	2 (18)	0
Upper respiratory tract infection	3 (30)	2 (18)	1 (17)
Cough	3 (30)	1 (9)	0
Infusion-related reaction	1 (10)	3 (27)	1 (17)
COVID-19	2 (20)	1 (9)	1 (17)
Ear infection	2 (20)	0 (0.0)	0
Epistaxis	0	2 (18)	1 (17)
Influenza-like illness	1 (10)	1 (9)	0
Oropharyngeal pain	1 (10)	1 (9)	1 (17)
Pyrexia	0	2 (18.2)	0
Sinusitis	1 (10)	1 (9)	0

- All TEAEs were Grade 1 or 2*
- No SAEs in patients treated with NTLA-2002
- 4 IRRs with NTLA-2002; 2 led to temporary interruption of study drug
 - Each instance resolved without sequelae and both patients received the full dose
- No clinically significant laboratory abnormalities
 - 1 patient had transient Grade 2 increase in ALT on Day 22

ALT, alanine aminotransferase; IRR, infusion-related reaction; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
 *Common Terminology Criteria for Adverse Events (CTCAE) Grading

A Single Dose of NTLA-2002 Showed Dose-Dependent and Durable Reductions in Plasma Kallikrein Protein Over Time



Number of patients

NTLA-2002 25 mg	10	10	10	10	10	6	6	4
NTLA-2002 50 mg	11	11	11	11	10	5	5	3
Placebo	6	6	6	5	5	4	3	

For post-baseline assessments, only scheduled visits completed by at least 3 patients in each arm are presented. Dashed line represents targeted minimum reduction. BL, baseline; SD, standard deviation.

This presentation includes data for an investigational product not yet approved by regulatory authorities.


Data cutoff date: 04Apr2024.

A Single Dose of NTLA-2002 Led to a Reduction in Monthly Angioedema Attack Rate Compared With Placebo

VARIABLE	NTLA-2002 25 mg (n=10)	NTLA-2002 50 mg (n=11)	Placebo (n=6)
Median follow-up (range), month	8.2 (4.4-11.8)	5.6 (2.9-11.5)	6.9 (1.9-12.5)
Weeks 1-16			
Mean no. of angioedema attacks per month (95% CI) ^a	0.7 (0.3, 2.0)	0.7 (0.2, 1.8)	2.8 (0.8, 9.9)
Percentage difference vs. placebo (95% CI)	-75% (-95%, 27%)	-77% (-95%, 15%)	
Weeks 5-16			
Mean no. of angioedema attacks per month (95% CI) ^a	0.6 (0.2, 1.9)	0.6 (0.2, 1.7)	3.1 (0.8, 11.8)
Percentage difference vs. placebo (95% CI)	-80% (-96%, 14%)	-81% (-97%, 3%)	

^aThe mean number of angioedema attacks per month was estimated using a negative binomial model with treatment arm and baseline attack rate as independent variables. Baseline is defined as the time from date of informed consent to randomization. A month is defined as 28 days.

Deep Reductions in Monthly HAE Attack Rate Compared to Placebo at Both Dose Levels




*95% CI of the mean attack rate percentage difference relative to placebo.

Following the 16-week primary observation period, patients were allowed to go back to their previous chronic prophylaxis therapy so no placebo comparisons can be made beyond week 16.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Data cutoff date: 04Apr2024.

Eight of 11 Patients Were Completely Attack Free Following a Single 50 mg Dose




The length of the gray bars indicates the interval from the start of the screening period to the last assessment as of the data cutoff date. Arrows indicate the patient is still on study.

The width of the colored bars indicates the duration of the attack. Black diamonds indicate when a patient resumed long-term prophylaxis, which was permitted after Week 16. Pt, patient.

Data cutoff date: 04Apr2024.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Eight of 11 Patients Were Completely Attack Free Following a Single 50 mg Dose



During Primary Observation Period

- Eight of 11 patients were completely attack free
- 10 of 11 patients with a clinically meaningful reduction in attacks

Post-Primary Observation Period*

- Eight of 11 patients remain completely attack free
- All 11 patients experienced clinically meaningful attack rate reduction with extended follow-up

*No placebo comparisons can be made beyond week 16, which is when patients were permitted to resume long-term prophylaxis.


The length of the gray bars indicates the interval from the start of the screening period to the last assessment as of the data cutoff date. Arrows indicate the patient is still on study.

The width of the colored bars indicates the duration of the attack. Black triangles indicate when a patient resumed long-term prophylaxis, which was permitted after week 16.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Data cutoff date: 04Apr2024.

Eight of 11 Patients Receiving a Single 50 mg Dose Experienced a Complete Response – Attack-Free and No Subsequent Treatment Required



NTLA-2002 Phase 2 Clinical Data Results Published in NEJM



The NEW ENGLAND
JOURNAL of MEDICINE

October 24, 2024

CRISPR-Based Therapy for Hereditary Angioedema

Danny M. Cohn, M.D., Ph.D., Padmalal Gurugama, M.D., Markus Magerl, M.D.,
Constance H. Katelaris, M.B., B.S., Ph.D., F.R.A.C.P., David Launay, M.D., Ph.D.,
Laurence Bouillet, M.D., Ph.D., Remy S. Petersen, M.D.,
Karen Lindsay, M.B., Ch.B., Emel Aygören-Pürsün, M.D., David Maag, Ph.D.,
James S. Butler, Ph.D., Mrinal Y. Shah, Ph.D., Adele Golden, Ph.D.,
Yuanxin Xu, M.D., Ph.D., Ahmed M. Abdelhady, Ph.D., David Lebwohl, M.D.,
and Hilary J. Longhurst, Ph.D., F.R.A.C.P.

Acknowledgements

This study is funded by Intellia Therapeutics.

We wish to extend our gratitude to:

- The patients, their caregivers, and their families
- Study site coordinators and staff
- The staff of Simbec-Orion for assistance with study management and operations support
- Medical writing and editorial support were provided by Adele Whaley, PhD, and Melissa Austin of Apollo Medical Communications, part of Helios Global Group, and funded by Intellia Therapeutics



Agenda

Welcome



Introduction

Dr. John Leonard *Chief Executive Officer, Intellia Therapeutics*



Review of NTLA-2002 Phase 2 Data

Dr. Danny Cohn *Internist, Department of Vascular Medicine, Amsterdam University Medical Center*



NTLA-2002 Clinical Development Update

Dr. David Lebwohl *Chief Medical Officer, Intellia Therapeutics*




Q&A

Dr. Paula Busse *Professor of Medicine – Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai*



Dr. Jim Butler *General Manager of NTLA-2002 Program, Intellia Therapeutics*

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Patients with Hereditary Angioedema (HAE)



Despite Available Treatments, Patients and Physicians are Highly Receptive to Target Profile of NTLA-2002

75%

of U.S. prescribers surveyed would offer a product with NTLA-2002's target profile to all patients within 3 years of launch

“ CRISPR has the potential to be a curative treatment, changing how we manage this disease.
- HAE Physician


Patients want better treatment options...

“ Treatment has definitely improved but I am still experiencing a high number of attacks.
- HAE Patient on lanadelumab, 24 attacks per year

“ I would love to not have to ever take another injection or another pill. It would be amazing.
- HAE Patient on lanadelumab, 8 attacks per year

“ I am hesitant to switch jobs because I know these are expensive treatments and I may not always have access.
- HAE Patient on lanadelumab, well-controlled

NTLA-2002 is a Potential Paradigm-Shift in Treating HAE Compared to Chronic, Long-Term Prophylaxis Therapies



For illustrative purposes only
NTLA-2002 is an investigational drug product that has not been approved by any regulatory agency.

WHERE WE ARE TODAY....

HAE patients are seeking improved efficacy and convenience to be free from disease and chronic treatment

Phase 2 data supports the potential of NTLA-2002 to eliminate attacks after a one-time treatment

Rapidly growing commercial opportunity with positive physician and patient receptivity to a potential one-time treatment

Recently initiated a global pivotal Phase 3 trial evaluating a single 50 mg dose of NTLA-2002 and Intellia is planning for a BLA submission in 2026¹

WHERE WE THINK WE'RE HEADED...

NTLA-2002 could be a functional cure for people living with HAE

Agenda

Welcome



Introduction

Dr. John Leonard *Chief Executive Officer, Intellia Therapeutics*



Review of NTLA-2002 Phase 2 Data

Dr. Danny Cohn *Internist, Department of Vascular Medicine, Amsterdam University Medical Center*



NTLA-2002 Clinical Development Update

Dr. David Lebwohl *Chief Medical Officer, Intellia Therapeutics*



Q&A

Dr. Paula Busse *Professor of Medicine – Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai*



Dr. Jim Butler *General Manager of NTLA-2002 Program, Intellia Therapeutics*

Q & A

NTLA-2002 Phase 2
Clinical Data Update

Intellia

THERAPEUTICS